NNC6022-0004

NNC6022-0004 is an investigational long-acting peptide developed by Novo Nordisk for the treatment of obesity. It is currently in early-stage clinical development, with Phase 1 trials evaluating its safety, tolerability, and pharmacokinetics in healthy individuals and people living with obesity. The compound is designed as a long-acting amylin analogue, targeting the amylin receptor to regulate appetite and promote weight loss. Amylin is a peptide hormone that works alongside insulin to control postprandial glucose levels and induce satiety. By mimicking the effects of endogenous amylin with a prolonged duration of action, NNC6022-0004 aims to provide a therapeutic option for chronic weight management.